Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 9/20 | 0.56 |
| ▸ | MMP2 | P08253 | 8/20 | 0.56 |
| ▸ | MMP3 | P08254 | 8/20 | 0.56 |
| ▸ | MMP1 | P03956 | 7/20 | 0.56 |
| ▸ | MMP7 | P09237 | 6/20 | 0.56 |
| ▸ | PYGL | P06737 | 10/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 2/20 | 0.44 |
| ▸ | MMP8 | P22894 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5194286 | 0.99 | MMP13 (0.54) | MMP13MMP2MMP3MMP1MMP7 | |
| SCHEMBL5192203 | 0.88 | MMP13 (0.46) | MMP13MMP2MMP3MMP1MMP7 | |
| SCHEMBL5192086 | 0.88 | PYGL (0.49) | PYGLCNR1CNR2CYP2C9 | |
| SCHEMBL5194927 | 0.88 | PYGL (0.49) | PYGLCNR1CNR2CYP2C9 | |
| SCHEMBL5195559 | 0.86 | PYGL (0.45) | MMP13MMP2MMP3MMP1MMP7 | |
| SCHEMBL5194492 | 0.85 | PYGL (0.48) | PYGLCYP2C9 | |
| SCHEMBL5196528 | 0.84 | MMP13 (0.55) | MMP13MMP2MMP3MMP1MMP7 | |
| SCHEMBL5427731 | 0.83 | PYGL (0.48) | PYGLCNR1CNR2CYP2C9 | |
| SCHEMBL5192583 | 0.82 | MMP13 (0.53) | MMP13MMP2MMP3MMP1MMP7 | |
| SCHEMBL5191862 | 0.81 | PYGL (0.55) | PYGLCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | PYGM, PYGL, GYS1 | MMP13 804/4885MMP2 625/4885MMP3 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.